Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL8036967 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL466239 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL685473 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL192129 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8099424 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075366 | 0.99 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 99030 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144783-A1 | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL NEUROPATHY, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT | ALTMEDICAL CO., LTD. (KR) | 2026-05-28 | — | — | US | claimed |
| EP-3727367-B1 | VITAMIN K2 COMPOSITIONS FOR USE IN THE TREATMENT OF DRUG INDUCED NEUROPATHY | SYNERGIA LIFE SCIENCES PVT LTD (IN) | 2026-05-27 | — | — | EP | claimed |
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094711-A | Methods for treating multiple myeloma comprising anti-CD 38 antibodies in combination with bortezomib, lenalidomide and dexamethasone | — | 2026-05-26 | — | — | CN | claimed |
| US-12636340-B2 | Methods of treating multiple myeloma | ONYX PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | EXAGEN INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2004016253-A1 | USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | WO | claimed |
| WO-2004016753-A2 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS | HUMAN GENOME SCIENCES, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2004010937-A2 | METHOD OF TREATING CANCER | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE AT INDIANA UNIVERSITY (US) | 2004-02-05 | — | — | WO | claimed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| WO-2004009784-A2 | NOVEL INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| WO-2004003545-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF MULTI-DRUG RESISTANCE BY HYALURONAN OLIGOMERS | TUFTS UNIVERSITY (US) | 2004-01-08 | — | — | WO | claimed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | claimed |
| WO-2003105835-A1 | METHODS OF USE FOR TRIPEPTIDYL PEPTIDASE II INHIBITORS AS ANTICANCER AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-12-24 | — | — | WO | claimed |